Skip to content
Companies

Fore Biotherapeutics

BRAF inhibitor for brain and solid tumors

  • Philadelphia, PA
  • Founded 2022
  • Biotech
  • fore.bio

Raised to date

$70.4M

of $109.6M offered across 1 Form D filing

Still open
$39.2M
Investors
20
Last filed
Jul 14, 2026

About

Fore Biotherapeutics is a clinical-stage precision oncology company developing targeted therapies for cancers driven by mutations that existing drugs miss. Its lead candidate, plixorafenib (formerly FORE8394), is a next-generation BRAF inhibitor being evaluated in the registration-intended FORTE Phase 2 master protocol, a global basket study across BRAF-altered advanced solid tumors, primary CNS tumors and thyroid cancers. In April 2026 the FDA granted plixorafenib Breakthrough Therapy Designation for adults with BRAF V600E-mutated high-grade glioma. The company runs as a largely virtual organization with its US headquarters at 3675 Market Street in Philadelphia and research ties in Rehovot, Israel.

Plixorafenib is a selective BRAF dimer breaker designed to hit a wider range of BRAF alterations - including non-V600 and fusion alterations - than earlier-generation BRAF inhibitors, and showed a 67% overall response rate in a pre-specified subgroup of MAPK-inhibitor-naive patients with BRAF V600-mutated primary CNS tumors.

Funding

  • EquityFiled Jul 14, 2026Form D/A
    $70.4M/ $109.6M

Product

Plixorafenib

Oncology drug candidate

An investigational, next-generation small-molecule BRAF inhibitor targeting a broad range of BRAF gene alterations in solid and CNS tumors, in registration-intended Phase 2 development.

  • Selective BRAF dimer breaker covering V600 and a wider set of BRAF alterations
  • Designed to overcome resistance limitations of earlier-generation BRAF inhibitors
  • FDA Breakthrough Therapy Designation for BRAF V600E-mutated high-grade glioma (April 2026)

Built for

Oncologists and neuro-oncologists treating adults and children whose advanced solid or primary CNS tumors carry BRAF alterations

People on file